A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PFIZER INC
PFE
$140.2B
Mkt Cap
$24.54
-1.88%
PFIZER INC (PFE) has a current P/E ratio of 18.0, compared to its historical median P/E of 16.9. The stock is currently considered Fair based on its historical valuation range.
PFIZER INC (PFE) has a 5-year average return on invested capital (ROIC) of 15.5%. This indicates strong capital allocation and a potential competitive advantage.
PFIZER INC (PFE) has a market capitalization of $140.6B. It is classified as a large-cap stock.
Yes, PFIZER INC (PFE) pays a dividend with a trailing twelve-month yield of 6.95%.
Based on historical P/E analysis, PFIZER INC (PFE) appears fair. The current P/E of 18.0 is 7% above its historical median of 16.9. The estimated fair value CAGR (P/E method) is -7.4%.
PFIZER INC (PFE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PFIZER INC (PFE) reported annual revenue of $62.6 billion in its most recent fiscal year, based on SEC EDGAR filings.
Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, and distributes biopharmaceutical products worldwide across developed and emerging markets. The company operates through three segments: Biopharma (its innovative science-based biopharmaceutical business and only reportable segment), PC1 (a contract development and manufacturing organization supplying specialty active pharmaceutical ingredients), and Pfizer Ignite (which is being discontinued). Within Biopharma, the company's commercial divisions are organized into Pfizer U.S. Commercial, Pfizer International Commercial, and Global Hospital and Biosimilars, which market and distribute products across Primary Care (including cardiovascular, metabolic, migraine, and vaccines), Specialty Care (inflammation & immunology, rare disease, and anti-infectives), Oncology (ADCs, small molecules, bispecifics, and immunotherapies), and Hospital and Biosimilars (off-patent branded and generic sterile injectables and biosimilars). Pfizer generates revenues primarily from the manufacture and sale of biopharmaceutical products, with a business model centered on delivering improved treatment outcomes and reducing healthcare costs such as emergency room visits and hospitalizations. The company pursues growth through advancing its internal product pipeline, maximizing value from existing marketed brands, and strategic business development activities including acquisitions and in-licensing agreements. R&D is managed through a single global organization led by the Chief Scientific Officer and President of Research and Development, with focus on oncology, internal medicine (cardiometabolic, weight management, migraine), vaccines, and inflammation and immunology, complemented by external partnerships with universities, biotechnology companies, and other firms to access innovative molecules and technologies.
【Pipeline-driven growth acceleration】 Management expects 2026 to be a rich year for catalysts, with approximately 20 pivotal study starts, eight key data readouts, and four regulatory decisions anticipated, concentrated in oncology, metabolic disease, and vaccines where the company has existing commercial infrastructure and scientific expertise. The company is targeting a first approval in 2028 from its obesity portfolio, specifically an ultra-long-acting GLP-1 receptor agonist with potential monthly dosing, and is advancing 20+ obesity trials including 10 phase III studies of this candidate. Following the VYNDAMAX patent settlement, management has clear line of sight to a high single-digit five-year revenue CAGR post-2028, with growth expected to be driven by the advancing R&D pipeline, previously executed business development initiatives, and ongoing progress of recently launched and acquired products. The company intends to maintain and grow its dividend over time while continuing to deliver long-term value, and is embedding artificial intelligence across R&D, commercial, manufacturing, and enterprise functions as a key strategic priority to drive productivity and accelerate innovation.
| Metric | Target | Period |
|---|---|---|
| Total company revenues | $59.5 billion–$62.5 billion | FY2026 |
| Adjusted diluted earnings per share | $2.80–$3.00 | FY2026 |
| COVID-19 product revenues | approximately $5 billion | FY2026 |
| Manufacturing optimization program savings | approximately $700 million | FY2026 |
Total company revenues (FY2026): “We continue to expect total company revenues in the range of $59.5 billion-$62.5 billion”
Adjusted diluted earnings per share (FY2026): “adjusted diluted earnings per share in the range of $2.80-$3.00 a share”
COVID-19 product revenues (FY2026): “Our COVID products are expected to trend lower again in 2026, with revenues of approximately $5 billion.”
Manufacturing optimization program savings (FY2026): “We continue to expect approximately $700 million in savings from our phase I of our manufacturing optimization program this year”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 63.3B | 62.6B | 63.6B | 59.6B | 101.2B | 81.3B |
| Net Income | 7.5B | 7.8B | 8.0B | 2.1B | 31.4B | 22.0B |
| EPS | $1.43 | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Free Cash Flow | 9.5B | 9.1B | 9.8B | 4.8B | 26.0B | 29.9B |
| ROIC | 0.0% | 7.5% | 8.1% | 2.5% | 33.1% | 26.1% |
| Gross Margin | - | 74.3% | 71.9% | 58.1% | 66.1% | 62.1% |
| Debt/Equity | 0.72 | 0.78 | 0.75 | 0.84 | 0.41 | 0.54 |
| Dividends/Share | $1.71 | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 |
| Operating Income | 0 | 10.2B | 11.1B | 3.2B | 35.9B | 25.1B |
| Operating Margin | 0.0% | 16.3% | 17.4% | 5.4% | 35.5% | 30.9% |
| ROE | 8.3% | 8.9% | 9.1% | 2.3% | 36.3% | 31.3% |
| Shares Outstanding | 5,731M | 5,714M | 5,696M | 5,727M | 5,735M | 5,709M |
PFIZER INC passes 3 of 9 quality checks, indicating weak fundamentals.
PFIZER INC trades at 18.0x trailing earnings, compared to its 15-year median P/E of 16.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 15.4x vs a median of 12.8x. The company's 5-year average ROIC is 15.5% with a gross margin of 66.5%. Total shareholder yield (dividends) is 7.0%. At current prices, the estimated annualized return to fair value is -1.2%.
PFIZER INC (PFE) has a net profit margin of 12.4%. This is a healthy margin.
PFIZER INC (PFE) generated $9.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PFIZER INC (PFE) has a debt-to-equity ratio of 0.78. This indicates moderate leverage.
PFIZER INC (PFE) reported earnings per share (EPS) of $1.36 in its most recent fiscal year.
PFIZER INC (PFE) has a return on equity (ROE) of 8.9%. This indicates moderate shareholder returns.
PFIZER INC (PFE) has a 5-year average gross margin of 66.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for PFIZER INC (PFE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PFIZER INC (PFE) has a book value per share of $15.13, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects 2026 to be a rich year for catalysts, with approximately 20 pivotal study starts, eight key data readouts, and four regulatory decisions anticipated, concentrated in oncology, metabolic disease, and vaccines where the company has existing commercial infrastructure and scientific expertise. The company is targeting a first approval in 2028 from its obesity portfolio, specifically an ultra-long-acting GLP-1 receptor agonist with potential monthly dosing, and is advancing 20+ obesity trials including 10 phase III studies of this candidate. Following the VYNDAMAX patent settlement, management has clear line of sight to a high single-digit five-year revenue CAGR post-2028, with growth expected to be driven by the advancing R&D pipeline, previously executed business development initiatives, and ongoing progress of recently launched and acquired products. The company intends to maintain and grow its dividend over time while continuing to deliver long-term value, and is embedding artificial intelligence across R&D, commercial, manufacturing, and enterprise functions as a key strategic priority to drive productivity and accelerate innovation.
Based on recent SEC filings and earnings calls, PFIZER INC (PFE) has provided the following forward guidance: Total company revenues: $59.5 billion–$62.5 billion (FY2026); Adjusted diluted earnings per share: $2.80–$3.00 (FY2026); COVID-19 product revenues: approximately $5 billion (FY2026); Manufacturing optimization program savings: approximately $700 million (FY2026).